Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Moving forward with metronomic chemotherapy: Meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology
Translational Oncology, Volume 4, No. 4, Year 2011
Notification
URL copied to clipboard!
Description
Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multi targeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology is still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marseille, France, and brought together clinicians, basic scientists, physician-scientists, trainees, and students from all around the world. The main aim of this international meeting was to provide a unique forum to 1) reflect on the major advances that have been made in this field of research since its creation, 2) communicate results from the most recent clinical trials and preclinical studies, 3) discuss the current and future challenges of the field, and 4) set forth a solid framework for future collaborative biologic and clinical studies. The present report documents the main preclinical and clinical data that were presented in the keynote and best abstract sessions and delivers the key messages from the meeting. © 2011 Neoplasia Press, Inc. All rights reserved.
Authors & Co-Authors
Pasquier, E.
Australia, Sydney
Unsw Sydney
Kieran, Mark W.
United States, Boston
Boston Children's Hospital
Sterba, Jaroslav
Czech Republic, Brno
Fakultni Nemocnice Brno
Shaked, Yuval
Israel, Haifa
Technion - Israel Institute of Technology
Baruchel, Sylvain
Canada, Toronto
Hospital for Sick Children University of Toronto
Oberlin, Odile
France, Villejuif
Institut de Cancerologie Gustave Roussy
Kivivuori, Maria Sanna
Finland, Helsinki
Children's Hospital Helsinki
Peyrl, Andreas
Austria, Vienna
Medizinische Universität Wien
Diawarra, Mamouna
Mali, Bamako
Hopital Gabriel Toure
Casanova, Michela
Italy, Milan
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan
Zacharoulis, Stergios
United Kingdom, London
The Royal Marsden Nhs Foundation Trust
Vassal, G.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Berthold, Frank
Germany, Koln
Uniklinik Köln
Verschuur, Arnauld
France, Marseille
Hopital la Timone
Andre, Nicolas
France, Marseille
Hopital la Timone
France, Marseille
Aix Marseille Université
France, Marseille
Metronomics Global Health Initiative
Statistics
Citations: 33
Authors: 15
Affiliations: 15
Identifiers
Doi:
10.1593/tlo.11124
e-ISSN:
19365233
Research Areas
Cancer